As COVID-19 vaccines ready themselves for market, two companies have turned their attention to what comes next – verifying whether the vaccines provide effective and lasting protection against SARS-CoV-2.

Researchers in the United States have estimated that the proportion of people in New York City who developed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the coronavirus disease 2019 (COVID-19) pandemic is around one in eight.

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, speaks with Stephen Russell, CEO of Vyriad. Dr. Russell reveals invaluable insights for those looking for or currently putting together partnership deals.

Imanis Life Sciences, LLC announced today upcoming presentations about the development and validation of IMMUNO-COV™, the first scalable, quantitative neutralizing antibody test for COVID-19.

Six months now into this perplexing and powerful pandemic, we’ve grown accustomed to seeing our “front line” heroes whenever we venture out and also when we don’t.

Mayo Clinic has licensed the Vyriad IMMUNO-COV™ antibody test that detects and quantifies neutralizing antibodies, the critical subset of antibodies known to protect against SARS-CoV-2 viral infections.

Vyriad and Imanis Life Sciences announced today the publication of a scientific paper on the development and validation of IMMUNO-COV™, a high-throughput clinical test to quantitatively measure SARS-CoV-2-neutralizing antibodies, the specific subset of anti-SARS-CoV-2 antibodies that block viral infection.

Imanis Life Sciences and Vyriad announced today the publication of a scientific paper on the development and validation of IMMUNO-COV™, a high-throughput clinical test to quantitatively measure SARS-CoV-2-neutralizing antibodies, the specific subset of anti-SARS-CoV-2 antibodies that block viral infection. The paper is available on bioRxiv, a free online archive and distribution service for non-peer-reviewed manuscripts […]

Vyriad, Inc. announced today that it has completed the development of a serology test to measure protective immunity against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Imanis Life Sciences will be exhibiting at the 2019 ASGCT annual meeting in Washington, DC, from Monday, April 29 through Wednesday, May 1. In addition, Rianna Vandergaast, Ph.D., a Senior Scientist at Imanis, will present during the Tools and Technologies Forum on Monday, April 29, 2019 at 4:15 PM ET. The presentation will highlight Imanis’ NIS […]

On January 21, Imanis Life Sciences moved to a new laboratory space in the Rochester Technology Campus. The new 25,000-square foot facility features molecular biology labs, several tissue culture spaces, as well as lab space designated for the performance of correlative testing for oncolytic virus clinical trials. Despite record low temperatures, the ribbon cutting ceremony […]

Imanis Life Sciences will be exhibiting at the upcoming World Molecular Imaging Congress 2018 (WMIC) in Seattle, WA between September 12-September 15th.  In addition, Imanis’ COO Kah-Whye Peng, Ph.D., will be presenting on “NIS reporter gene imaging to accelerate development of virus, gene and cell therapies” as part of the MILabs Industry Workshop.  Join Dr. […]

The American Society of Gene and Cell Therapy held their 21st annual meeting in Chicago from May 16-19. The meeting welcomed thousands of attendees from science, industry, and patient advocacy groups. Imanis was represented with a booth, several poster presentations, and a place in the Tools and Technologies Forum. Through these forums, we demonstrated how […]

Imanis was strongly represented at the 11th annual International Oncolytic Virus Conference in Oxford, England. The conference, which took place April 9-12, welcomed scientists from basic science, translational science, medicine, biotech, and big pharma. Imanis CEO Stephen Russell, M.D. Ph.D., founded the conference 11 years ago with John Bell, Ph.D. In the past decade, the […]

Several of our expert scientists are attending the Society of Toxicology (SOT) to present Imanis’ groundbreaking work in preclinical noninvasive imaging. The conference is being held in San Antonio, Texas from March 11-15. We are excited to reveal our cutting edge advancements with NIS, the Sodium Iodide Symporter, with two poster presentations: 1. Precise Anatomical […]

On October 11-12, Imanis will be presenting our latest products and services with a booth at the LabRoots’ Cancer Research and Oncology Virtual Event. You can register for the event for free here, and join the thousands of scientists, professionals, and clinicians who will be in attendance. The event will be live for two days, […]

Imanis turns five years old in September! Since we opened in 2012, we have built a broad selection of products and services to assist our fellow scientists. It has been our mission to promote the adoption of noninvasive imaging with our high-quality reporter gene imaging reagents. We feel privileged to collaborate and work with leaders […]

Two abstracts submitted by the hardworking scientists at Imanis were recently selected to advance to the final round for consideration as innovation of the year at WMIC!  WMIC (World Molecular Imaging Congress) is led by academic and industry professionals who have been recognized for their achievements in molecular imaging. The congress is taking place from […]

On August 13, the Imanis team had the pleasure of preparing dinner at the Rochester Ronald McDonald House. Since 1974, Ronald McDonald House has been dedicated to creating and supporting programs that directly improve the well-being of children and their families. We were happy to give a small amount of our time to the organization […]

Imanis is excited to release a new video series showcasing our connections with leaders in the field of preclinical in vivo imaging, starting with Dr. Freek Beekman! We welcomed Dr. Freek Beekman to our offices on June 7. He was visiting Rochester, MN from his home in the Netherlands to give a presentation at Mayo Clinic. While visiting at Imanis, we […]